BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol. 2005;79:8400-8409. [PMID: 15956584 DOI: 10.1128/jvi.79.13.8400-8409.2005] [Cited by in Crossref: 187] [Cited by in F6Publishing: 124] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Hargett AA, Marcella AM, Yu H, Li C, Orwenyo J, Battistel MD, Wang LX, Freedberg DI. Glycosylation States on Intact Proteins Determined by NMR Spectroscopy. Molecules 2021;26:4308. [PMID: 34299586 DOI: 10.3390/molecules26144308] [Reference Citation Analysis]
2 Quadeer AA, Louie RHY, McKay MR. Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them. Nat Commun 2019;10:2073. [PMID: 31061402 DOI: 10.1038/s41467-019-09819-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
3 Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA, Krey T. Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. J Virol 2015;89:2170-81. [PMID: 25473061 DOI: 10.1128/JVI.02190-14] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 9.4] [Reference Citation Analysis]
4 Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, Patel AH, Foung SK. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog 2014;10:e1004297. [PMID: 25122476 DOI: 10.1371/journal.ppat.1004297] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
5 Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF. Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses 2012;4:2016-30. [PMID: 23202451 DOI: 10.3390/v4102016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
6 Vigerust DJ, Ulett KB, Boyd KL, Madsen J, Hawgood S, McCullers JA. N-linked glycosylation attenuates H3N2 influenza viruses. J Virol 2007;81:8593-600. [PMID: 17553891 DOI: 10.1128/JVI.00769-07] [Cited by in Crossref: 134] [Cited by in F6Publishing: 87] [Article Influence: 9.6] [Reference Citation Analysis]
7 Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, Mariuzza RA, Foung SKH. Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. Proc Natl Acad Sci U S A 2016;113:E6946-54. [PMID: 27791171 DOI: 10.1073/pnas.1614942113] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
8 Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol. 2006;80:8695-8704. [PMID: 16912317 DOI: 10.1128/jvi.00271-06] [Cited by in Crossref: 186] [Cited by in F6Publishing: 134] [Article Influence: 12.4] [Reference Citation Analysis]
9 Fénéant L, Levy S, Cocquerel L. CD81 and hepatitis C virus (HCV) infection. Viruses 2014;6:535-72. [PMID: 24509809 DOI: 10.3390/v6020535] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
10 Poon AF, Lewis FI, Pond SL, Frost SD. Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope. PLoS Comput Biol 2007;3:e11. [PMID: 17238283 DOI: 10.1371/journal.pcbi.0030011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 3.1] [Reference Citation Analysis]
11 Ankavay M, Montpellier C, Sayed IM, Saliou JM, Wychowski C, Saas L, Duvet S, Aliouat-Denis CM, Farhat R, de Masson d'Autume V, Meuleman P, Dubuisson J, Cocquerel L. New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle. Sci Rep. 2019;9:6243. [PMID: 31000788 DOI: 10.1038/s41598-019-42737-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
12 D’Arienzo V, Moreau A, D’Alteroche L, Gissot V, Blanchard E, Gaudy-Graffin C, Roch E, Dubois F, Giraudeau B, Plantier JC. Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host. J Virol. 2013;87:13609-13618. [PMID: 24109215 DOI: 10.1128/jvi.02119-13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
13 Cui J, Smith T, Robbins PW, Samuelson J. Darwinian selection for sites of Asn-linked glycosylation in phylogenetically disparate eukaryotes and viruses. Proc Natl Acad Sci U S A 2009;106:13421-6. [PMID: 19666543 DOI: 10.1073/pnas.0905818106] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
14 Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011;8:161. [PMID: 21477382 DOI: 10.1186/1743-422x-8-161] [Cited by in Crossref: 89] [Cited by in F6Publishing: 64] [Article Influence: 8.9] [Reference Citation Analysis]
15 Iacob RE, Perdivara I, Przybylski M, Tomer KB. Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J Am Soc Mass Spectrom. 2008;19:428-444. [PMID: 18187336 DOI: 10.1016/j.jasms.2007.11.022] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
16 Mazalovska M, Kouokam JC. Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections. Biomed Res Int 2018;2018:3750646. [PMID: 29854749 DOI: 10.1155/2018/3750646] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
17 Guest JD, Pierce BG. Computational Modeling of Hepatitis C Virus Envelope Glycoprotein Structure and Recognition. Front Immunol 2018;9:1117. [PMID: 29892287 DOI: 10.3389/fimmu.2018.01117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
18 Tong Y, Lavillette D, Li Q, Zhong J. Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. Front Immunol 2018;9:1411. [PMID: 29971069 DOI: 10.3389/fimmu.2018.01411] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
19 Stejskal L, Lees WD, Moss DS, Palor M, Bingham RJ, Shepherd AJ, Grove J. Flexibility and intrinsic disorder are conserved features of hepatitis C virus E2 glycoprotein. PLoS Comput Biol 2020;16:e1007710. [PMID: 32109245 DOI: 10.1371/journal.pcbi.1007710] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
20 Sabahi A. Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J. 2009;6:117. [PMID: 19643019 DOI: 10.1186/1743-422x-6-117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
21 Sabo MC, Luca VC, Ray SC, Bukh J, Fremont DH, Diamond MS. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology 2012;422:174-84. [PMID: 22078164 DOI: 10.1016/j.virol.2011.10.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
22 Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol 2012;86:12923-32. [PMID: 22993159 DOI: 10.1128/JVI.02052-12] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
23 Gershoni JM. B-cell restriction - an alternative piece to the puzzle. Hum Vaccin Immunother 2019;15:2044-9. [PMID: 30945969 DOI: 10.1080/21645515.2019.1600989] [Reference Citation Analysis]
24 Sabahi A, Uprichard SL, Wimley WC, Dash S, Garry RF. Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol 2014;88:10280-8. [PMID: 24991010 DOI: 10.1128/JVI.00874-14] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
25 Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol. 2007;81:8072-8079. [PMID: 17507469 DOI: 10.1128/jvi.00459-07] [Cited by in Crossref: 108] [Cited by in F6Publishing: 68] [Article Influence: 7.7] [Reference Citation Analysis]
26 Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Foung SK, Ball JK, Patel AH. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol. 2008;89:653-659. [PMID: 18272755 DOI: 10.1099/vir.0.83386-0] [Cited by in Crossref: 113] [Cited by in F6Publishing: 113] [Article Influence: 8.7] [Reference Citation Analysis]
27 Tabll A, Abbas AT, El-Kafrawy S, Wahid A. Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World J Hepatol 2015; 7(22): 2369-2383 [PMID: 26464752 DOI: 10.4254/wjh.v7.i22.2369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Hargett AA, Renfrow MB. Glycosylation of viral surface proteins probed by mass spectrometry. Curr Opin Virol 2019;36:56-66. [PMID: 31202133 DOI: 10.1016/j.coviro.2019.05.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
29 Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res. 2014;105:100-111. [PMID: 24583033 DOI: 10.1016/j.antiviral.2014.02.013] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
30 Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212 [PMID: 29527256 DOI: 10.4254/wjh.v10.i2.186] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 16.3] [Reference Citation Analysis]
31 Krey T, d’Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, Petitpas I, Johansson DX, Tawar RG, Baron B, Robert B. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010;6:e1000762. [PMID: 20174556 DOI: 10.1371/journal.ppat.1000762] [Cited by in Crossref: 176] [Cited by in F6Publishing: 165] [Article Influence: 16.0] [Reference Citation Analysis]
32 Helle F, Duverlie G, Dubuisson J. The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses. 2011;3:1909-1932. [PMID: 22069522 DOI: 10.3390/v3101909] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 7.1] [Reference Citation Analysis]
33 Kachko A, Loesgen S, Shahzad-Ul-Hussan S, Tan W, Zubkova I, Takeda K, Wells F, Rubin S, Bewley CA, Major ME. Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol Pharm 2013;10:4590-602. [PMID: 24152340 DOI: 10.1021/mp400399b] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
34 Vigerust DJ, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 2007;15:211-218. [PMID: 17398101 DOI: 10.1016/j.tim.2007.03.003] [Cited by in Crossref: 351] [Cited by in F6Publishing: 326] [Article Influence: 25.1] [Reference Citation Analysis]
35 Wang SF, Lee YM, Chan YJ, Liu HF, Yen YF, Liu WT, Huang JC, Chen YM. Influenza A virus in Taiwan, 1980-2006: Phylogenetic and antigenic characteristics of the hemagglutinin gene. J Med Virol 2009;81:1457-70. [PMID: 19551820 DOI: 10.1002/jmv.21531] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
36 Urbaczek AC, Ximenes VF, Afonso A, Generoso WC, Nogueira CT, Tansini A, Cappelini LT, Malagó Júnior W, da Silva FH, da Fonseca LM, da Costa PI. Recombinant hepatitis C virus-envelope protein 2 interactions with low-density lipoprotein/CD81 receptors. Mem Inst Oswaldo Cruz 2015;110:534-42. [PMID: 26018451 DOI: 10.1590/0074-02760140441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Ashfaq UA, Qasim M, Yousaf MZ, Awan MT, Jahan S. Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies. J Transl Med. 2011;9:194. [PMID: 22074322 DOI: 10.1186/1479-5876-9-194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
38 Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol 2007;81:1821-37. [PMID: 17151111 DOI: 10.1128/JVI.02098-06] [Cited by in Crossref: 86] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
39 Ciczora Y, Callens N, Penin F, Pécheur EI, Dubuisson J. Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J Virol 2007;81:2372-81. [PMID: 17166909 DOI: 10.1128/JVI.02198-06] [Cited by in Crossref: 68] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
40 Swanson MD, Boudreaux DM, Salmon L, Chugh J, Winter HC, Meagher JL, André S, Murphy PV, Oscarson S, Roy R, King S, Kaplan MH, Goldstein IJ, Tarbet EB, Hurst BL, Smee DF, de la Fuente C, Hoffmann HH, Xue Y, Rice CM, Schols D, Garcia JV, Stuckey JA, Gabius HJ, Al-Hashimi HM, Markovitz DM. Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. Cell 2015;163:746-58. [PMID: 26496612 DOI: 10.1016/j.cell.2015.09.056] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
41 Mirnurollahi SM, Bolhassani A, Irani S, Davoudi N. Expression and Purification of HCV Core and Core-E1E2 Proteins in Different Bacterial Strains. Iran J Biotechnol 2015;13:57-62. [PMID: 28959300 DOI: 10.15171/ijb.1249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, Ball JK, Pierce BG, Mariuzza RA, Foung SKH, Fuerst TR. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells. J Virol 2019;93:e01403-18. [PMID: 30651366 DOI: 10.1128/JVI.01403-18] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 15.5] [Reference Citation Analysis]
43 Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J. Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol. 2013;87:7593-7607. [PMID: 23637397 DOI: 10.1128/jvi.02824-12] [Cited by in Crossref: 61] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
44 Al Olaby RR, Cocquerel L, Zemla A, Saas L, Dubuisson J, Vielmetter J, Marcotrigiano J, Khan AG, Vences Catalan F, Perryman AL, Freundlich JS, Forli S, Levy S, Balhorn R, Azzazy HM. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. PLoS One 2014;9:e111333. [PMID: 25357246 DOI: 10.1371/journal.pone.0111333] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
45 Izquierdo L, Oliveira C, Fournier C, Descamps V, Morel V, Dubuisson J, Brochot E, Francois C, Castelain S, Duverlie G, Helle F. Hepatitis C Virus Resistance to Carbohydrate-Binding Agents. PLoS One 2016;11:e0149064. [PMID: 26871442 DOI: 10.1371/journal.pone.0149064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
46 Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the Inhibition of Viral Infections. Molecules 2015;20:14051-81. [PMID: 26247927 DOI: 10.3390/molecules200814051] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 8.7] [Reference Citation Analysis]
47 Whidby J, Mateu G, Scarborough H, Demeler B, Grakoui A, Marcotrigiano J. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J Virol 2009;83:11078-89. [PMID: 19710151 DOI: 10.1128/JVI.00800-09] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
48 Brown RJ, Koutsoudakis G, Urbanowicz RA, Mirza D, Ginkel C, Riebesehl N, Calland N, Albecka A, Price L, Hudson N, Descamps V, Backx M, McClure CP, Duverlie G, Pecheur EI, Dubuisson J, Perez-del-Pulgar S, Forns X, Steinmann E, Tarr AW, Pietschmann T, Ball JK. Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. J Virol 2014;88:667-78. [PMID: 24173227 DOI: 10.1128/JVI.01745-13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Bagno FF, Godói LC, Figueiredo MM, Sérgio SAR, Moraes TFS, Salazar NC, Kim YC, Reyes-Sandoval A, da Fonseca FG. Chikungunya E2 Protein Produced in E. coli and HEK293-T Cells-Comparison of Their Performances in ELISA. Viruses 2020;12:E939. [PMID: 32858804 DOI: 10.3390/v12090939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Beljelarskaya SN, Orlova OV, Drutsa VL, Orlov VA, Timohova AV, Koroleva NN, Popenko VI, Ivanov AV, Spirin PV, Prassolov VS, Rubtsov PM, Kochetkov SN. Hepatitis C virus: The role of N-glycosylation sites of viral genotype 1b proteins for formation of viral particles in insect and mammalian cells. Biochem Biophys Rep 2016;7:98-105. [PMID: 28955895 DOI: 10.1016/j.bbrep.2016.05.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
51 Hundt J, Li Z, Liu Q. Post-translational modifications of hepatitis C viral proteins and their biological significance. World J Gastroenterol 2013; 19(47): 8929-8939 [PMID: 24379618 DOI: 10.3748/wjg.v19.i47.8929] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
52 Prentoe J, Velázquez-Moctezuma R, Augestad EH, Galli A, Wang R, Law M, Alter H, Bukh J. Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. Proc Natl Acad Sci U S A 2019;116:10039-47. [PMID: 31040211 DOI: 10.1073/pnas.1822002116] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
53 Di Lorenzo C, Angus AG, Patel AH. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011;3:2280-300. [PMID: 22163345 DOI: 10.3390/v3112280] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
54 Rothwangl KB, Manicassamy B, Uprichard SL, Rong L. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virol J 2008;5:46. [PMID: 18355410 DOI: 10.1186/1743-422X-5-46] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
55 LeBlanc EV, Kim Y, Capicciotti CJ, Colpitts CC. Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies. Pathogens 2021;10:685. [PMID: 34205894 DOI: 10.3390/pathogens10060685] [Reference Citation Analysis]
56 Meredith LW, Farquhar MJ, Tarr AW, McKeating JA. Type I interferon rapidly restricts infectious hepatitis C virus particle genesis. Hepatology 2014;60:1891-901. [PMID: 25066844 DOI: 10.1002/hep.27333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
57 Brown RJ, Hudson N, Wilson G, Rehman SU, Jabbari S, Hu K, Tarr AW, Borrow P, Joyce M, Lewis J. Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol. 2012;86:11956-11966. [PMID: 22855498 DOI: 10.1128/jvi.01079-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
58 Martínez-Donato G, Capdesuñer Y, Acosta-Rivero N, Rodríguez A, Morales-Grillo J, Martínez E, González M, Alvarez-Obregon JC, Dueñas-Carrera S. Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice. Mol Biotechnol 2007;35:225-35. [PMID: 17652786 DOI: 10.1007/BF02686008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
59 Wang Y, Wang J, Wu S, Zhu H. The unexpected structures of hepatitis C virus envelope proteins. Exp Ther Med 2017;14:1859-65. [PMID: 28962094 DOI: 10.3892/etm.2017.4745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
60 Evans DeWald L, Starr C, Butters T, Treston A, Warfield KL. Iminosugars: A host-targeted approach to combat Flaviviridae infections. Antiviral Res 2020;184:104881. [PMID: 32768411 DOI: 10.1016/j.antiviral.2020.104881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Russell RS, Kawaguchi K, Meunier JC, Takikawa S, Faulk K, Bukh J, Purcell RH, Emerson SU. Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles. J Viral Hepat 2009;16:621-32. [PMID: 19302336 DOI: 10.1111/j.1365-2893.2009.01111.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
62 Guo Y, Yu H, Zhong Y, He Y, Qin X, Qin Y, Zhou Y, Zhang P, Zhang Y, Li Z, Jia Z. Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation. Medicine (Baltimore) 2018;97:e0208. [PMID: 29642144 DOI: 10.1097/MD.0000000000010208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
63 Carlsen TH, Scheel TK, Ramirez S, Foung SK, Bukh J. Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry. J Virol 2013;87:1385-99. [PMID: 23152512 DOI: 10.1128/JVI.00684-12] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
64 Vasiliauskaite I, Owsianka A, England P, Khan AG, Cole S, Bankwitz D, Foung SKH, Pietschmann T, Marcotrigiano J, Rey FA, Patel AH, Krey T. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. mBio 2017;8:e00382-17. [PMID: 28512091 DOI: 10.1128/mBio.00382-17] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
65 Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol. 2007;81:8101-8111. [PMID: 17522218 DOI: 10.1128/jvi.00127-07] [Cited by in Crossref: 158] [Cited by in F6Publishing: 101] [Article Influence: 11.3] [Reference Citation Analysis]
66 Omran MH, Nabil W, Youssef SS, El-Sayed M, El Awady MK. Heterogeneity and new epitopes of hepatitis C virus genotype 4. Hepat Mon 2013;13:e10521. [PMID: 24130599 DOI: 10.5812/hepatmon.10521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
67 Clarke JL, Paruch L, Dobrica MO, Caras I, Tucureanu C, Onu A, Ciulean S, Stavaru C, Eerde A, Wang Y, Steen H, Haugslien S, Petrareanu C, Lazar C, Popescu CI, Bock R, Dubuisson J, Branza-Nichita N. Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination. Plant Biotechnol J 2017;15:1611-21. [PMID: 28419665 DOI: 10.1111/pbi.12743] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
68 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
69 Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, Leroux-Roels G, Palmer KE, Dubuisson J. Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother. 2011;55:5159-5167. [PMID: 21896910 DOI: 10.1128/aac.00633-11] [Cited by in Crossref: 95] [Cited by in F6Publishing: 70] [Article Influence: 9.5] [Reference Citation Analysis]
70 Zhang Y, Chen P, Cao R, Gu J. Mutation of putative N-linked glycosylation sites in Japanese encephalitis virus premembrane and envelope proteins enhances humoral immunity in BALB/C mice after DNA vaccination. Virol J 2011;8:138. [PMID: 21439032 DOI: 10.1186/1743-422X-8-138] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
71 Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol. 2008;82:6061-6066. [PMID: 18400849 DOI: 10.1128/jvi.02475-07] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 6.9] [Reference Citation Analysis]
72 Tarr AW, Khera T, Hueging K, Sheldon J, Steinmann E, Pietschmann T, Brown RJ. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses 2015;7:3995-4046. [PMID: 26193307 DOI: 10.3390/v7072809] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
73 Guan M, Wang W, Liu X, Tong Y, Liu Y, Ren H, Zhu S, Dubuisson J, Baumert TF, Zhu Y. Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem. 2012;287:35631-35645. [PMID: 22927442 DOI: 10.1074/jbc.m112.382341] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
74 Wang S, Guo F, Liu K, Wang H, Rao S, Yang P, Jiang C. Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2. Virus Res 2008;136:8-15. [PMID: 18554741 DOI: 10.1016/j.virusres.2008.03.004] [Cited by in F6Publishing: 71] [Reference Citation Analysis]
75 Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Foung SK. A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol 2008;82:6067-72. [PMID: 18385242 DOI: 10.1128/JVI.00252-08] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
76 Lavie M, Hanoulle X, Dubuisson J. Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. Front Immunol 2018;9:910. [PMID: 29755477 DOI: 10.3389/fimmu.2018.00910] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 14.0] [Reference Citation Analysis]
77 Takebe Y, Saucedo CJ, Lund G, Uenishi R, Hase S, Tsuchiura T, Kneteman N, Ramessar K, Tyrrell DL, Shirakura M, Wakita T, McMahon JB, O'Keefe BR. Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One 2013;8:e64449. [PMID: 23700478 DOI: 10.1371/journal.pone.0064449] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 9.1] [Reference Citation Analysis]
78 Li HF, Huang CH, Ai LS, Chuang CK, Chen SS. Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry. J Biomed Sci. 2009;16:89. [PMID: 19778418 DOI: 10.1186/1423-0127-16-89] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
79 Hamed MR, Brown RJ, Zothner C, Urbanowicz RA, Mason CP, Krarup A, McClure CP, Irving WL, Ball JK, Harris M, Hickling TP, Tarr AW. Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. J Innate Immun 2014;6:676-84. [PMID: 24854201 DOI: 10.1159/000362209] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
80 Singaravelu R, Blais DR, McKay CS, Pezacki JP. Activity-based protein profiling of the hepatitis C virus replication in Huh-7 hepatoma cells using a non-directed active site probe. Proteome Sci. 2010;8:5. [PMID: 20181094 DOI: 10.1186/1477-5956-8-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
81 Bhatia M, Gupta E. Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature. J Family Med Prim Care 2020;9:531-8. [PMID: 32318377 DOI: 10.4103/jfmpc.jfmpc_943_19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
82 Yu X, Sainz B Jr, Petukhov PA, Uprichard SL. Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother 2012;56:6109-20. [PMID: 22948883 DOI: 10.1128/AAC.01413-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
83 Stoddard MB, Li H, Wang S, Saeed M, Andrus L, Ding W, Jiang X, Learn GH, von Schaewen M, Wen J, Goepfert PA, Hahn BH, Ploss A, Rice CM, Shaw GM. Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. mBio 2015;6:e02518. [PMID: 25714714 DOI: 10.1128/mBio.02518-14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
84 Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung SK, Mariuzza RA. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem 2015;290:10117-25. [PMID: 25737449 DOI: 10.1074/jbc.M115.643528] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
85 Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM. Studying hepatitis C virus: making the best of a bad virus. J Virol. 2007;81:8853-8867. [PMID: 17522203 DOI: 10.1128/jvi.00753-07] [Cited by in Crossref: 98] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
86 Monteiro JT, Lepenies B. Myeloid C-Type Lectin Receptors in Viral Recognition and Antiviral Immunity. Viruses 2017;9:E59. [PMID: 28327518 DOI: 10.3390/v9030059] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
87 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
88 Ashfaq UA, Masoud MS, Khaliq S, Nawaz Z, Riazuddin S. Inhibition of hepatitis C virus 3a genotype entry through Glanthus Nivalis Agglutinin. Virol J 2011;8:248. [PMID: 21599979 DOI: 10.1186/1743-422X-8-248] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
89 Law JLM, Logan M, Wong J, Kundu J, Hockman D, Landi A, Chen C, Crawford K, Wininger M, Johnson J, Mesa Prince C, Dudek E, Mehta N, Tyrrell DL, Houghton M. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. J Virol 2018;92:e02141-17. [PMID: 29540595 DOI: 10.1128/JVI.02141-17] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
90 Zhang XL, Qu H. The Role of Glycosylation in Infectious Diseases. Adv Exp Med Biol 2021;1325:219-37. [PMID: 34495538 DOI: 10.1007/978-3-030-70115-4_11] [Reference Citation Analysis]
91 Idrees S, Ashfaq UA, Khaliq S. HCV Envelope protein 2 sequence comparison of Pakistani isolate and In-silico prediction of conserved epitopes for vaccine development. J Transl Med 2013;11:105. [PMID: 23631455 DOI: 10.1186/1479-5876-11-105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
92 Bianchi A, Crotta S, Brazzoli M, Foung SK, Merola M. Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virions. Int J Hepatol 2011;2011:968161. [PMID: 22007314 DOI: 10.4061/2011/968161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
93 Bagdonaite I, Wandall HH. Global aspects of viral glycosylation. Glycobiology 2018;28:443-67. [PMID: 29579213 DOI: 10.1093/glycob/cwy021] [Cited by in Crossref: 109] [Cited by in F6Publishing: 86] [Article Influence: 36.3] [Reference Citation Analysis]
94 Li H, McMahon BJ, McArdle S, Bruden D, Sullivan DG, Shelton D, Deubner H, Gretch DR. Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology 2008;375:580-91. [PMID: 18343477 DOI: 10.1016/j.virol.2008.02.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
95 Jahan S, Samreen B, Khaliq S, Ijaz B, Khan M, Siddique MH, Ahmad W, Hassan S. HCV entry receptors as potential targets for siRNA-based inhibition of HCV. Genet Vaccines Ther. 2011;9:15. [PMID: 21896165 DOI: 10.1186/1479-0556-9-15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
96 Kalemera MD, Capella-Pujol J, Chumbe A, Underwood A, Bull RA, Schinkel J, Sliepen K, Grove J. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins. J Gen Virol 2021;102. [PMID: 33147126 DOI: 10.1099/jgv.0.001512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
97 Shahid M, Qadir A, Yang J, Ahmad I, Zahid H, Mirza S, Windisch MP, Shahzad-Ul-Hussan S. An Engineered Microvirin Variant with Identical Structural Domains Potently Inhibits Human Immunodeficiency Virus and Hepatitis C Virus Cellular Entry. Viruses 2020;12:E199. [PMID: 32054060 DOI: 10.3390/v12020199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Kant Upadhyay R. Biomarkers in Japanese encephalitis: a review. Biomed Res Int 2013;2013:591290. [PMID: 24455705 DOI: 10.1155/2013/591290] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
99 Urbanowicz RA, McClure CP, King B, Mason CP, Ball JK, Tarr AW. Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. J Gen Virol 2016;97:2265-79. [PMID: 27384448 DOI: 10.1099/jgv.0.000537] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
100 Fishman SL, Murray JM, Eng FJ, Walewski JL, Morgello S, Branch AD. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis. 2008;197:597-607. [PMID: 18275278 DOI: 10.1086/526519] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
101 Nayak A, Pattabiraman N, Fadra N, Goldman R, Kosakovsky Pond SL, Mazumder R. Structure-function analysis of hepatitis C virus envelope glycoproteins E1 and E2. J Biomol Struct Dyn 2015;33:1682-94. [PMID: 25245635 DOI: 10.1080/07391102.2014.967300] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
102 Jahan S, Khaliq S, Samreen B, Ijaz B, Khan M, Ahmad W, Ashfaq UA, Hassan S. Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV. Virol J. 2011;8:295. [PMID: 21663667 DOI: 10.1186/1743-422x-8-295] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
103 Lavillette D, Pécheur EI, Donot P, Fresquet J, Molle J, Corbau R, Dreux M, Penin F, Cosset FL. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol 2007;81:8752-65. [PMID: 17537855 DOI: 10.1128/JVI.02642-06] [Cited by in Crossref: 127] [Cited by in F6Publishing: 72] [Article Influence: 9.1] [Reference Citation Analysis]
104 Kim Y, Vaughan K, Greenbaum J, Peters B, Law M, Sette A. A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). PLoS One 2012;7:e38028. [PMID: 22675428 DOI: 10.1371/journal.pone.0038028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
105 Bernardi A, Huang Y, Harris B, Xiong Y, Nandi S, McDonald KA, Faller R. Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain. PLoS One 2020;15:e0237295. [PMID: 32756606 DOI: 10.1371/journal.pone.0237295] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
106 Dent M, Hamorsky K, Vausselin T, Dubuisson J, Miyata Y, Morikawa Y, Matoba N. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. Cell Mol Gastroenterol Hepatol 2021;11:185-98. [PMID: 32861832 DOI: 10.1016/j.jcmgh.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Russell RS, Meunier JC, Takikawa S, Faulk K, Engle RE, Bukh J, Purcell RH, Emerson SU. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci USA. 2008;105:4370-4375. [PMID: 18334634 DOI: 10.1073/pnas.0800422105] [Cited by in Crossref: 137] [Cited by in F6Publishing: 136] [Article Influence: 10.5] [Reference Citation Analysis]
108 Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 2007;81:374-83. [PMID: 17050612 DOI: 10.1128/JVI.01134-06] [Cited by in Crossref: 187] [Cited by in F6Publishing: 126] [Article Influence: 12.5] [Reference Citation Analysis]
109 Li Y, Wang G, Wang J, Man K, Yang Q. Cell attenuated porcine epidemic diarrhea virus strain Zhejiang08 provides effective immune protection attributed to dendritic cell stimulation. Vaccine 2017;35:7033-41. [PMID: 29100707 DOI: 10.1016/j.vaccine.2017.10.052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
110 Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol 2007; 13(17): 2406-2415 [PMID: 17552023 DOI: 10.3748/wjg.v13.i17.2406] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 87] [Article Influence: 6.7] [Reference Citation Analysis]
111 Callens N, Ciczora Y, Bartosch B, Vu-Dac N, Cosset FL, Pawlotsky JM, Penin F, Dubuisson J. Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol 2005;79:15331-41. [PMID: 16306604 DOI: 10.1128/JVI.79.24.15331-15341.2005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
112 Alhammad YM, Maharajh S, Butcher R, Eden JS, White PA, Poumbourios P, Drummer HE. Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection. PLoS One 2015;10:e0126397. [PMID: 25970466 DOI: 10.1371/journal.pone.0126397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
113 Logan M, Law J, Wong JAJ, Hockman D, Landi A, Chen C, Crawford K, Kundu J, Baldwin L, Johnson J, Dahiya A, LaChance G, Marcotrigiano J, Law M, Foung S, Tyrrell L, Houghton M. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. J Virol 2017;91:e01552-16. [PMID: 27795422 DOI: 10.1128/JVI.01552-16] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
114 Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010;84:10159-68. [PMID: 20668082 DOI: 10.1128/JVI.01180-10] [Cited by in Crossref: 153] [Cited by in F6Publishing: 106] [Article Influence: 13.9] [Reference Citation Analysis]
115 Rychłowska M, Owsianka AM, Foung SKH, Dubuisson J, Bieńkowska-Szewczyk K, Patel AH. Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J Gen Virol 2011;92:2249-61. [PMID: 21697343 DOI: 10.1099/vir.0.034314-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
116 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M, Lemon SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol 2011;85:7005-19. [PMID: 21543495 DOI: 10.1128/JVI.00586-11] [Cited by in Crossref: 102] [Cited by in F6Publishing: 72] [Article Influence: 10.2] [Reference Citation Analysis]
118 Toth EA, Chagas A, Pierce BG, Fuerst TR. Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development. Viruses 2021;13:1027. [PMID: 34072451 DOI: 10.3390/v13061027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol. 2014;96:535-548. [PMID: 25015956 DOI: 10.1189/jlb.4ri0214-126r] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
120 Knight RL, Schultz KL, Kent RJ, Venkatesan M, Griffin DE. Role of N-linked glycosylation for sindbis virus infection and replication in vertebrate and invertebrate systems. J Virol 2009;83:5640-7. [PMID: 19297464 DOI: 10.1128/JVI.02427-08] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
121 Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, Castelain S, Roingeard P, Duverlie G, Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol. 2010;84:11905-11915. [PMID: 20844034 DOI: 10.1128/jvi.01548-10] [Cited by in Crossref: 144] [Cited by in F6Publishing: 107] [Article Influence: 13.1] [Reference Citation Analysis]
122 Min YQ, Duan XC, Zhou YD, Kulinich A, Meng W, Cai ZP, Ma HY, Liu L, Zhang XL, Voglmeir J. Effects of microvirin monomers and oligomers on hepatitis C virus. Biosci Rep 2017;37:BSR20170015. [PMID: 28507200 DOI: 10.1042/BSR20170015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
123 Vieyres G, Dubuisson J, Pietschmann T. Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion. Viruses. 2014;6:1149-1187. [PMID: 24618856 DOI: 10.3390/v6031149] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
124 Delang L, Coelmont L, Neyts J. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses 2010;2:826-66. [PMID: 21994657 DOI: 10.3390/v2040826] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]